1,154
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: MEDICAL ONCOLOGY

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

ORCID Icon, ORCID Icon, , ORCID Icon, , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 20-27 | Received 13 Jun 2019, Accepted 10 Aug 2019, Published online: 29 Aug 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Arne Strauss, Marianne Schmid, Michael Rink, Michael Moran, Stephan Bernhardt, Marcus Hubbe, Lothar Bergmann, Katrin Schlack & Martin Boegemann. (2021) Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma According to Risk Factors: The STAR-TOR Registry. Future Oncology 17:18, pages 2325-2338.
Read now

Articles from other publishers (3)

Bruce Li, Swati Sood, Melissa J. Huynh & Nicholas E. Power. (2024) Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients. JU Open Plus 2:4.
Crossref
Na Li, Jie Chen, Qiang Liu, Hongyi Qu, Xiaoqing Yang, Peng Gao, Yao Wang, Huayu Gao, Hong Wang & Zuohui Zhao. (2021) Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma. PeerJ 9, pages e11901.
Crossref
Fatma Bugdayci Basal, Cengiz Karacin, Irem Bilgetekin & Omur Berna Oksuzoglu. (2021) Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?. Urologia Internationalis 105:7-8, pages 666-673.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.